Atea Pharmaceuticals Inc. Company Profile
NASDAQ: AVIRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Atea Pharmaceuticals at a glance
Atea Pharmaceuticals Inc. (NASDAQ: AVIR) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Boston, MA. Atea Pharmaceuticals is led by Dr. Jean-Pierre Sommadossi Ph.D. and employs about 55 people. The company's shares have traded publicly since 2020.
At a market capitalization of $413.5 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001593899, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Atea Pharmaceuticals do?
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Business description based on the company's public filings.
Company information
- Legal name
- Atea Pharmaceuticals Inc.
- Ticker
- NASDAQ: AVIR
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Jean-Pierre Sommadossi Ph.D.
- Employees
- 55
- Headquarters
- 225 Franklin Street, Boston, MA, United States
- Phone
- 857 284 8891
- Website
- ateapharma.com
- IPO year
- 2020
- Market cap
- $413.46M
- SEC CIK
- 0001593899
Companies similar to Atea Pharmaceuticals
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| DMACDiaMedica Therapeutics Inc. | 8.01 | +0.25% | $431.94M | vs AVIR |
| PRTAProthena Corporation plc | 8.61 | +1.53% | $442.01M | vs AVIR |
| KMDAKamada Ltd. | 7.78 | -1.46% | $448.70M | vs AVIR |
| RZLTRezolute Inc. | 4.64 | +5.94% | $448.79M | vs AVIR |
| SPRYARS Pharmaceuticals Inc. | 4.56 | +4.59% | $453.48M | vs AVIR |
| IRDOpus Genetics Inc. | 4.46 | +1.13% | $371.05M | vs AVIR |
| OVIDOvid Therapeutics Inc. | 2.34 | -0.85% | $457.00M | vs AVIR |
| GALTGalectin Therapeutics Inc. | 3.64 | +0.55% | $367.09M | vs AVIR |